Solid Tumors Clinical Trial
Official title:
Phase 1/2 Study of Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors
This is a Phase 1/2, open-label, monocentric, dose-escalation study of lenalidomide in combination with cetuximab in subjects with solid tumors. The primary objective is to establish the maximum tolerated dose (MTD) of lenalidomide in combination with cetuximab in patients with solid tumors including colorectal cancer (CRC), squamous cell carcinoma of the head and neck (SCCHN) and non-small cell lung cancer (NSCLC).
Background: For metastatic cancer such as head and neck, lung and colorectal cancer,
standard therapy comprises chemotherapy regimen partially in combination with monoclonal
antibodies blocking the vascular endothelial growth factor (VEGF) or the epidermal growth
factor receptor (EGFR). When disease progression occurs during or after these treatment
options have been applied, no established therapy is available and the clinical development
of new strategies is warranted. Lenalidomide (Revlimid®) is a thalidomide derivative and
belongs to the so-called ImiDs, a class of immunostimulatory molecules. IMiDs have profound
effects on the immune system. Obviously, IMiDs are able to function as co-stimulatory
molecule for mature T cells. In addition, IMiDs are able to mitigate the negative effects of
CTLA-4 signalling. On the molecular level, IMiDs induce phosphorylation of CD28, underlining
the concept that they act as costimulatory signals during T cell activation. Furthermore,
the induction of specific CTL responses by dendritic cells (DC) is enhanced and the activity
of suppressive regulatory T cells (Treg) inhibited.
In addition to their effects on cells of the adaptive immune system, IMiDs also target the
innate immune response. Natural killer cells (NK) as well as natural killer T-cells (NKT)
are activated by Immunomodulatory Drugs (IMiDs), and the effects of IMiDs on NK and NKT
cells might further contribute to the immune-activating properties of ImiDs.
Therefore the rationale of the combination of lenalidomide with a therapeutic IgG1 antibody
such as cetuximab (Erbitux®) is based on the fact that several reports suggest a role of
antibody-dependent cellular cytotoxicity (ADCC) as a mode of action of cetuximab.
However, the exact definition of these anti-cancer mechanisms of lenalidomide alone and in
combination with cetuximab in vivo require further investigation in early clinical trials.
The goal of this phase I/II trial is to define the toxicity of the combination of
lenalidomide and cetuximab and to study potential effects on the tumor and the immune
system.
Subjects meeting all inclusion criteria will be enrolled in cohorts of three patients to
receive a single, oral dose of lenalidomide administered on Days 1-28 and intravenous (IV)
infusions of cetuximab (400 mg/m2 first infusion only, then 250 mg/m2 subsequently)
administered on Days 1, 8, 15, and 22 of each 28-day cycle.
Prior to combination therapy, there will be a 21 day lead in treatment period with
lenalidomide monotherapy (Days -21 to -1). Combination treatment will start at Day 1. Tumor
biopsies will be taken before monotherapy lenalidomide treatment (between d-25 and -22) and
between Day -3 and -1 (before starting cetuximab). A third tumor biopsy will be taken
between Cycle 1 Day 21 and 28 after starting combination therapy. Cycles will be repeated
every 28 days. All subjects will continue on study drug until disease progression,
unacceptable toxicity or treatment discontinuation for any other reason. The MTD of
lenalidomide will be defined as the highest dose level at which no more than 1 out of 6
subjects experience a dose-limiting toxicity (DLT) during the first cycle of administration
in combination with cetuximab. Safety measurements and analysis will be performed at each
visit.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT00750841 -
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
|
Phase 1 | |
| Withdrawn |
NCT05419817 -
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
|
Phase 2 | |
| Completed |
NCT02828930 -
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
|
Phase 1 | |
| Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
| Completed |
NCT03258515 -
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
|
Phase 1 | |
| Terminated |
NCT03225105 -
M3541 in Combination With Radiotherapy in Solid Tumors
|
Phase 1 | |
| Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
| Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
| Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
| Active, not recruiting |
NCT03634982 -
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04685226 -
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT06036121 -
A Study of ADRX-0706 in Select Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
| Completed |
NCT01528046 -
Metformin in Children With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05325866 -
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
| Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT01940601 -
Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors
|
Phase 2 |